307990-40-5

Basic information

• Product Name: 3-bromo-5-trifluoromethylphenylisocyanate
• Synonyms: 3-bromo-5-trifluoromethylphenylisocyanate
• CAS NO: 307990-40-5
• Molecular Weight: 266.017
• Mol File: 307990-40-5.mol
• Article Data: 4

Chemical Properties

• CAS DataBase Reference: 3-bromo-5-trifluoromethylphenylisocyanate(CAS DataBase Reference)
• NIST Chemistry Reference: 3-bromo-5-trifluoromethylphenylisocyanate(307990-40-5)
• EPA Substance Registry System: 3-bromo-5-trifluoromethylphenylisocyanate(307990-40-5)

Safety Data

• Hazardous Substances Data: 307990-40-5(Hazardous Substances Data)

Upstream product

• 54962-75-3 [3-bromo-5-(trifluoromethyl)phenyl]amine 
• 503-38-8 trichloromethyl chloroformate 
• 32315-10-9 bis(trichloromethyl) carbonate 

Relevant articles and documents

Discovery of novel VEGFR-2 inhibitors. Part 5: Exploration of diverse hinge-binding fragments via core-refining approach

Pathological angiogenesis plays a critical role in numerous diseases including malignancy. VEGFR-2 is the central regulators in angiogenesis and has become a promising target for anticancer drug design. We have identified a novel biphenyl-aryl urea incorporated with salicyladoxime (BPS-7) as potent VEGFR-2 inhibitor. As a continuation to our previous research, various aromatic-heterocyclic were introduced as hinge-binding fragment via a core-refining approach. Interestingly, many compounds exhibited comparable VEGFR-2 inhibition to Sorafenib. In particular, 12e and 12o displayed excellent VEGFR-2 inhibitory activity with IC50 values of 0.50 nM and 0.79 nM, respectively. Several title compounds showed considerable antiproliferative activity against A549 and SMMC-7721 cells. In addition, molecular docking was performed to rationalize the efficiency of the better compounds. These results will be instructive for further inhibitor design and optimization.

GLUCAGON ANTAGONISTS/INVERSE AGONISTS

A novel class of compounds, which act to antagonize the action of the glucagon hormone on the glucagon receptor. Owing to their antagonizing effect of the glucagon receptor the compounds may be suitable for the treatment and/or prevention of any glucagon-